FABRAZYME® (Agalsidase beta) is used in the treatment of Fabry Disease by replacing a missing enzyme that lowers the amount of GL-3 being deposited in the lining of blood vessels.

FABRAZYME® is manufactured by Sanofi Genzyme.

Administration and Dosage:

Administration of FABRAZYME® is by bi-weekly intravenous infusion.


FABRAZYME® is indicated to treat:

  • Fabry Disease

Common Side Effects:

The more common side effects of FABRAZYME® include severe allergic (anaphylaxis) and hypersensitivity reactions, infusion-associated reactions, upper respiratory tract infection, chills, fever, headache, cough, burning and/or tingling sensation, fatigue, swelling in the legs, dizziness and rash.

More information:

Please read the full Prescribing Information for FABRAZYME® and discuss any questions you have with your doctor.


We are happy to help!